Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673805 | 1.00 | ERBB2 (0.66) | ERBB2MINK1 | |
| SCHEMBL5751111 | 0.98 | ERBB2 (0.70) | ERBB2MINK1 | |
| SCHEMBL5751103 | 0.98 | ERBB2 (0.70) | ERBB2MINK1 | |
| SCHEMBL5751242 | 0.93 | ERBB2 (0.72) | ERBB2MINK1 | |
| SCHEMBL5751235 | 0.93 | ERBB2 (0.72) | ERBB2MINK1 | |
| SCHEMBL5753154 | 0.90 | ERBB2 (0.70) | ERBB2MINK1 | |
| SCHEMBL5753151 | 0.90 | ERBB2 (0.70) | ERBB2MINK1 | |
| SCHEMBL6582677 | 0.89 | ERBB2 (0.57) | ERBB2MINK1 | |
| SCHEMBL6582675 | 0.89 | ERBB2 (0.57) | ERBB2MINK1 | |
| SCHEMBL5752630 | 0.89 | ERBB2 (0.66) | ERBB2MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286063-A1 | GNRH agonist combination drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-20070179097-A1 | GnRH agonist combination drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-08-02 | — | — | US | disclosed |
| US-20050215528-A1 | Breast cancer, precocious puberty, endometriosis, hysteromyoma, Alzheimer's disease, circulatory organ disease, menopausal syndrome, metastasis, premenstrual tension, dysmenorrhea or calcium/phosphorus bone dysbolism; combined with selective estrogen receptor modulator (SERM); side effect reduction | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-29 | — | — | US | disclosed |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040116330-A1 | Diagnosing or specifying a growth factor receptor expressed in cancer cells, and selectively inhibiting all or a part of the growth factor receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1424080-A1 | GNRH AGONIST COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6716863-B2 | TYROSINE KINASE INHIBITORS; ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040024035-A1 | Heterocyclic compounds, their production and use | TASAKA AKIHIRO (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1350793-A1 | MEDICINAL COMPOSITIONS HAVING IMPROVED ABSORBABILITY | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| EP-1350792-A1 | MEDICINAL COMPOSITIONS IMPROVED IN SOLUBLITY IN WATER | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| EP-1268473-A1 | OXAZOLE DERIVATIVES AND THEIR USES AS TYROSINE KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020173526-A1 | Heterocyclic compounds their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| WO-2001077107-A1 | OXAZOLE DERIVATIVES AND THEIR USES AS TYROSINE KINASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286063-A1 | GNRH agonist combination drugs | GNRHR, FSHR, EDNRA | ERBB2 1062/4885MINK1 1352/4885 |
| US-20040024035-A1 | Heterocyclic compounds, their production and use | ABL1, ROS1, MAPK1 | ERBB2 6/4885MINK1 340/4885 |
| US-20020173526-A1 | Heterocyclic compounds their production and use | ABL1, ROS1, MAPK1 | ERBB2 8/4885MINK1 258/4885 |
| US-20050215528-A1 | Breast cancer, precocious puberty, endometriosis, hysteromyoma, Alzheimer's disease, circulatory organ disease, menopausal syndrome, metastasis, premenstrual tension, dysmenorrhea or calcium/phosphorus bone dysbolism; combined with selective estrogen receptor modulator (SERM); side effect reduction | GNRHR, BRCA1, SHBG | ERBB2 744/4885MINK1 1439/4885 |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | ERBB2, EGFR, ABCG2 | ERBB2 1/4885MINK1 3888/4885 |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | EGFR, ERBB2, ERBB3 | ERBB2 2/4885MINK1 2919/4885 |
| US-20070179097-A1 | GnRH agonist combination drugs | GNRHR, FSHR, EDNRA | ERBB2 1062/4885MINK1 1352/4885 |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | EGFR, ERBB2, ERBB3 | ERBB2 2/4885MINK1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.